Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Cholangiocarcinoma 6Gastrointestinal Neoplasms 3Carcinoma, Transitional Cell 3Breast Neoplasms 3Pancreatic Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Solid Tumor, Miscellaneous 1Solid Tumor 1Sarcoma 1Recurrence 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lung Neoplasms 1Locally Advanced Unresectable Gastric Cancer 1Liposarcoma 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1Gastrointestinal Stromal Tumors 1Fibroblast Growth Factors (FGFs)/Fibroblast Growth Factor Receptors (FGFRs) Genetic Aberration Gastric Cancer, INCB054828, Paclitaxel 1Digestive System Neoplasms 1Advanced Non-Small Cell Lung Cancer 1Advanced Non Small Cell Lung Cancer 1

Interventions

Capecitabine 6Irinotecan 5Fluorouracil 5Cisplatin 5Oxaliplatin 4Leucovorin 4Gemcitabine 4apatinib 3Sorafenib 3Bevacizumab 3tislelizumab 2pembrolizumab 2Sunitinib 2Radiotherapy 2Paclitaxel 2Immune Checkpoint Inhibitors 2Cyclophosphamide 2Cetuximab 2Aspirin 2Ascorbic Acid 2130-nm albumin-bound paclitaxel 2spartalizumab 1sintilimab 1regorafenib 1pyrotinib 1pemigatinib 1lutetium Lu 177 dotatate 1huachansu 1halofantrine 1guadecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Digestive System Neoplasms × pemigatinib × Clear all
NCT05913661 2023-06-22

Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Unknown
30 enrolled
Gastrointestinal

Carcinoma, Digestive System Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡